The inherent expertise of CMOs and CDMOs is believed to be capable of enabling reduction in the time-to-market a product, significant cost-benefits, as well as access to larger production capacities and novel technologies. It is worth mentioning that there has been substantial merger and acquisition activity in the pharma CMO market in the past few years, as players strive to become one stop shops, in order to cater to the diverse needs of pharmaceutical developers (ranging from early-stage development to commercial production). Considering the ongoing innovation in production technologies, evolving pipeline of small molecule products and the increasing demand for such drug candidates, we believe that the pharma CMO market is likely to witness positive growth in the coming years.
Players Engaged in Offering Pharma CMO Services
Close to 500 companies claim to offer CMO manufacturing services to pharmaceutical companies across the globe
Geographical Location of Manufacturing Facilities
Majority of the pharma CMO facilities are located in Asia-Pacific region, followed by Europe and North America.
More Than USD 9 Billion has been Invested by Pharma CMOCompanies for Expansion of their Capacities / Capabilities across the Globe between 2017 and 2021
The last five years have witnessed ample increase in the number of expansion initiatives undertaken by pharma CMO companies to expand development and manufacturing operations.
Owing to the rising competition among pharmaceutical and biologics contract manufacturers and pressing need to reduce drug development timelines, the pharmaceutical contract manufacturing market is anticipated to witness ample increase in the coming decade.
To get a detailed information on the key players, regulatory landscape, mergers and acquisitions, expansions, demand, installed capacity and the likely market evolution, you can also download the SAMPLE REPORT on pharmaceutical CMO by Roots Analysis.